Antiphospholipid Syndrome (APS)
15
7
8
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
6.7%
1 terminated out of 15 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (15)
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Follow-up Cohort of Patients With Antiphospholipid Syndrome
Pilot Study of Gut Commensals in Antiphospholipid Syndrome
Hematological Disorders in EHPVO Patients
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs
Effect of Belimumab on Antibody Titers in Primary APS Patients